Registered title, quoted from ClinicalTrials.gov
A Phase II Study of SKB571 in Patients With Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07230405, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC .
Inclusion criterion 2
Subjects who have received strong cytochrome P450 (CYP3A4) inhibitors or inducers, or BCRP inhibitors within 2 weeks prior to the first dose of study treatment or within 5 half-lives of known drug, whichever is longer.
Exclusion criterion 11
Subjects who have received chemotherapy, immunotherapy, or biological therapy within 4 weeks prior to the first dose of study treatment.
Exclusion criterion 12
Subjects with active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study treatment.
Exclusion criterion 13
Subjects with any disease requiring systemic treatment with corticosteroids (prednisone at doses > 10 mg/d or similar drugs with equivalent doses) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment.
Exclusion criterion 14
Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1.
Inclusion criterion 4
Subjects with other malignant tumors within 3 years prior to the first dose.
Exclusion criterion 2
Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C.
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07230405, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subjects aged 18-75 years at the time of signing the informed consent form
- Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC .
- Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1.
- Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1.
- Subjects who are assessed by the investigator to have an expected survival of ≥ 12 weeks.
- Subjects who have adequate organ function.
- Subjects who have recovered from all toxicities due to prior therapy .
- Male and female subjects must agree to use highly effective contraception methods during the study treatment.
- Subjects who voluntarily sign the informed consent form.
Exclusion Criteria:
- Subjects with known active or untreated central nervous system (CNS) metastases.
- Subjects with other malignant tumors within 3 years prior to the first dose.
- Subjects with history of major cardiovascular, cerebrovascular, or thromboembolic disease.
- Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C.
- Uncontrolled pleural effusion, pericardial effusion, or ascites effusion requiring repeated drainage.
- Subjects with known allergy or hypersensitivity to SKB571 or its excipients.
- Subjects with clinically severe lung injuries due to pulmonary complications.
- History of noninfectious pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD
- Subjects with major surgery within 28 days prior to the first dose.
- Subjects who have received live vaccines within 30 days prior to the first dose of study treatment, or who are scheduled to receive live vaccines during the study.
- Subjects who have received strong cytochrome P450 (CYP3A4) inhibitors or inducers, or BCRP inhibitors within 2 weeks prior to the first dose of study treatment or within 5 half-lives of known drug, whichever is longer.
- Subjects who have received chemotherapy, immunotherapy, or biological therapy within 4 weeks prior to the first dose of study treatment.
- Subjects with active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study treatment.
- Subjects with any disease requiring systemic treatment with corticosteroids (prednisone at doses > 10 mg/d or similar drugs with equivalent doses) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment.
- Any condition that, in the opinion of the investigator, will interfere with the assessment of study treatment or the safety of the subject or the interpretation of the study results.
Quoted from ClinicalTrials.gov, NCT07230405, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07230405, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.